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The majority of cases of Charcot-Marie-Tooth type 1A
(CMT1A) and of hereditary neuropathy with a liability to
pressure palsies (HNPP) are the result of heterozygosity for the
duplication or deletion of peripheral myelin protein 22 gene
(PMP22) on 17p11.2. Southern blots, pulsed-field gel electro-
phoresis (PFGE), fluorescence in situ hybridization (FISH) and
polymorphic marker analysis are currently used diagnostic
methods. But they are time-consuming, labor-intensive and
have some significant limitations. We describe a rapid real-
time quantitative PCR method for determining gene copy
number for the identification of DNA duplication or deletion
occurring in CMT1A or HNPP and compare the results
obtained with REP-PCR. Six patients with CMT1A and 14
patients with HNPP [confirmed by Repeat (REP)-PCR], and
16 patients with suspicious CMT1A and 13 patients with
suspicious HNPP [negative REP-PCR], and 15 normal controls
were studied. We performed REP-PCR, which amplified a 3.6
Kb region (including a 1.7 Kb recombination hotspot), using
specific CMT1A-REP and real-time quantitative PCR on the
LightCycler system. Using a comparative threshold cycle (Ct)
method and -globin as a reference gene, the gene copy β
number of the PMP22 gene was quantified. The PMP22
duplication ratio ranged from 1.35 to 1.74, and the PMP22
deletion ratio from 0.41 to 0.53. The PMP22 ratio in normal
controls ranged from 0.81 to 1.12. All 6 patients with CMT1A
and 14 patients with HNPP confirmed by REP-PCR were
positive by real-time quantitative PCR. Among the 16
suspicious CMT1A and 13 suspicious HNPP with negative
REP-PCR, 2 and 4 samples, respectively, were positive by
real-time quantitative PCR. Real-time quantitative PCR is a
more sensitive and more accurate method than REP-PCR for
the detection of PMP22 duplications or deletions, and it is also
faster and easier than currently available methods. Therefore,
we believe that the real-time quantitative method is useful for
diagnosing CMT1A and HNPP.
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INTRODUCTION
The majority of Charcot-Marie-Tooth 1(CMT1)
patients possess DNA rearrangements, which are
the molecular causes of their disease. A 1.5-Mb
tandem duplication, the CMT1A duplication,
accounts for approximately 70 percent of CMT1
cases, and a deletion of the same 1.5-Mb region
in chromosome 17p11.2 is found in >85 percent
of patients with HNPP. The CMT1A duplication
and HNPP deletion result from unequal crossing-
over and reciprocal homologous recombination
involving a 24-Kb repeat-CMT1A-REP-which
flanks the 1.5-Mb region. A meiotic recombination
hotspot occurs within CMT1A-REP. The majority
of the de novo duplication and deletion events
occur during male germ cell meiosis. The CMT1A
and HNPP phenotypes result from a gene dosage
effect. CMT1A is due to trisomic overexpression
of the peripheral myelin protein-22 gene (PMP22)
whereas HNPP results from the monosomic un-
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derexpression of PMP22. Moreover, in rare cases
PMP22 point mutations can cause disease in
patients without the CMT1A duplication or the
HNPP deletion.
1
In molecular genetic testing for the CMT1A du-
plication and the HNPP deletion, several ap-
proaches are available. Molecular diagnosis by
hybridization-based methods include; Southern
blotting,
2-5 quantitative photostimulated lumi-
nescence (PSL) imaging,
6-9 and pulse-field gel elec-
trophoresis (PFGE).
2,5,10-12 Less frequently used
methods include fluorescence-in situ hybridiza-
tion (FISH),
13,14 polymorphic markers,
12,15 repeat
(REP-) PCR,
16-18 and endpoint quantitative PCR.
19,20
But, these methods have several disadvantages for
the diagnosis of CMT1A and HNPP.
In this study, we describe a rapid real-time
quantitative PCR devised to assess gene copy
number for the identification of DNA duplication
or deletion occurring in CMT1A or HNPP, and we
compare the results obtained with REP-PCR.
MATERIALS AND METHODS
Subjects and DNA extraction
Six patients with CMT1A and 14 patients with
HNPP (confirmed by REP-PCR), 16 suspicious
CMT1A and 13 suspicious HNPP patients with
negative REP-PCR, and 15 normal controls were
studied. Genomic DNA was extracted from
EDTA-treated blood using the MagNa Pure LC
DNA isolation kit and instrument (Roche), ac-
cording to the manufacturer's instructions. DNA
analysis was carried out with 'informed consent'.
REP-PCR
REP-PCR was performed as denscribed by
Stronach et al.
17 The method amplifies a 3.6 Kb
region, including the recombination 1.7 Kb hot-
spot, from specific CMT1A-REP. A schematic of
the method is shown in Fig. 1.
Fig. 1. Schematic method of REP-
PCR. The junctional CMT1A-REPs
shown exhibit crossing-over within
the 3.2 Kb region.Real-time Quantitative PCR for the Diagnosis of CMT1A and HNPP
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Real-time quantitative PCR
Primers and probes used for real-time quan-
titative PCR were designed using LightCycler
Probe Design Software version 1.0 (Roche). The
amplified fragment (202 bp), including exon 5 of
the PMP22 gene, was obtained using forward
primer 5'-ACC CAG TGC ATC CAA C-3' and
reverse primer 5'-ATC CAT AGC ACC ATT TCA
AAG-3'. The sequence of the sensor probe was
5'-CGG CTT GTG GCA TTG GCA-Fluorescein-3',
and the sequence of the anchor probe 5'-LCRed
640-CTT GCC CTT ACA GGT GGA GTA TCT-3'.
The primers and probes of the β-globin gene in
LightCycler Control DNA kit (Roche) were used
as reference. Amplification was carried out using
the LightCycler FastStart DNA Master Hybridi-
zation Probe kit (Roche) in a standard PCR con-
taining; 0.5μmol/L of each primer and 0.2 μmol/
L of each probe in a 20μL final volume containing
2μL of sample. The cycling program consisted of
an initial denaturation at 95 for 10 min, and 45
cycles of 95 for 10 sec, 58 for 10 sec, and 72
for 9 sec. Amplifications of PMP22 and β-globin
were performed simultaneously in each capillary
tube. Each test was repeated three times.
Calculating the gene copy number
Using a comparative threshold cycle (Ct)
method, as previously described by Livak,
21 and
β-globin as a reference gene, the gene copy
number by PMP22 gene duplication or deletion
was quantified and calculated.
RESULTS
The amplification curves for PMP22 and the β-
globin gene are shown in Fig. 2. The Ct values of
PMP22 and of the β-globin gene were almost the
same in the normal sample, whereas the Ct values
of PMP22 in CMT1A and HNPP were decreased
or increased, respectively, versus that of β-globin
in the amplification curve. The PMP22 duplication
ratio in two CMT1A patients, confirmed by REP-
PCR, ranged from 1.35 to 1.74, the PMP22 deletion
ratio in 14 patients with HNPP, as confirmed by
REP-PCR, ranged from 0.41 to 0.53 and the PMP22
ratio in the controls ranged from 0.81 to 1.12
(Table 1). The standard deviations of Ct were 0.22,
0.18 and 0.24 in CMT1A, HNPP and controls, re-
spectively. Six patients with CMT1A and the 14
patients with HNPP, as confirmed by REP-PCR,
were positive by real-time quantitative PCR.
Among the 16 suspicious CMT1A and 13 suspi-
cious HNPP patients, with a negative REP-PCR, 2
and 4 samples, respectively, were positive by real-
time quantitative PCR. Therefore, the real-time
quantitative PCR method can be more detected
50% (2/4) of the CMT1A patients and 22.2% (4/
18) of the HNPP patients with cross-over in
CMT1A-REP. The measured copy numbers of the
Fig. 2. Amplification curves of PMP22 and of the β-
globin gene in HNPP (A), normal (B) and CMT1A (C)
subjects. In normal sample, the Ct values of PMP22 and
of the -globin gene were almost the same (middle), β
whereas the Ct values of PMP22 in HNPP and CMT1A
were increased (upper) or decreased (lower), respectively,
versus that of -globin in the amplification curve. β
A
B
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15 normal controls, and in the 2 CMT1A and 14
HNPP patients are shown in Fig. 3. No overlap of
copy number was found between CMT1A or
HNPP patients and the controls.
DISCUSSION
At least nine loci for CMT1 and four for CMT2
have been identified by genetic linkage studies.
Six of the genes associated with CMT1, and re-
cently one gene for CMT2, has been identified.
Although at least eight loci are associated with the
aCMT1 phenotype, 70 to 90% of patients possess
the causative CMT1A duplication. Deletion of the
same genomic segment that is duplicated in
CMT1A leads to a clinically distinct neuropathy-
HNPP.
1 Recombination events occur within the
1.7 Kb hotspot located between an EcoRI site,
unique to the proximal CMT1A-REP, and a NsiI
site, unique to distal CMT1A-REP. It has been
reported that the recombination rate in hotspot
region ranges from 75 to 87% in a population-
dependent manner.
1 In the present study, the re-
combination rate in the hotspot region was about
73% (16/22), which is similar to that obtained in
other populations.
Several methods for detecting the CMT1A
duplication and the HNPP deletion are available
currently. Recently, the real-time quantitative PCR
method has been used to detect haploidy and
triploidy in genetic diseases and cancer.
22-25 Detec-
tion of the PMP22 duplication and deletion by
real-time quantitative PCR using TaqMan probes
has been know as a fast method allowing to be
diagnosed in 2 hr. However, specific probes are
requiredin real-time quantitative PCR using
TaqMan probes.
In the present study, this method also can be
more found 27% (6/22) of duplication and dele-
tion and is more sensitive than REP-PCR. However,
many more samples should be tested for CMT1A
duplication ratio. For mutation studies in the
PMP22 gene, P0 gene (CMT1B), connexin32 gene
(CMT1X),
26 or another subtype of CMT is needed
in samples without duplication or deletion.
27 One
case of CMT1A patient with 1.87 of gene copy
number was presumed homozygote duplication,
but it should be confirmed by other reference
method e.g. FISH.
The reaction efficiencies varied in the different
experiments, thus it may not be possible to obtain
similar efficiencies for both control and target
markers. This limitation also affects highly accu-
rate systems such as the LightCycler instrument.
But the gene dosage test in the method described
is feasible and more accurate. In this study, the
mean CV of the Ct value of the PMP22 and - β
globin genes was < 2.0% in between run. There-
fore, it appears that results of real-time quanti-
tative PCR were accurate and reproducible.
Table 1. Peripheral Myelin Protein 22 (PMP22) Duplication and Deletion Ratios Detected by Real Time Quantitative
PCR in CMT1A and HNPP and in Normal Controls, Confirmed by REP PCR
Samples
PMP22 ratio
Mean Range SD* of Ct value
Control (n= 15) 0.95 0.81-1.12 0.24
CMT1A (n=6) 1.55 1.35-1.74 0.22
HNPP (n=14) 0.47 0.41-0.53 0.18
*Standard deviation.
Fig. 3. Measured copy numbers of the PMP22 gene per
haploid genome in 15 normal controls ( ), 6 CMT1A ( )
and 14 HNPP ( ). No overlap of gene copy number
between each groups.Real-time Quantitative PCR for the Diagnosis of CMT1A and HNPP
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In conclusion, real-time quantitative PCR is
both more sensitive and more accurate than REP-
PCR in terms of the detection of PMP22 dupli-
cations or deletions. It is also faster and easier
than other currently available methods and clearly
differentiates gene dose. Therefore, real-time
quantitative PCR method may be useful for diag-
nosing CMT1A and HNPP, and may be applied
to the diagnosis of any disease caused by gene
dosage changes.
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